Access

Published online 19 May 2008 | Nature | doi:10.1038/news.2008.842

News

Embryonic stem-cell trial put on hold

Future clinical test still waiting for the go-ahead.

Monya Baker

The first potential clinical trial of a cell therapy derived from embryonic stem (ES) cells has been put on hold by the US Food and Drug Administration (FDA). Researchers say this reflects the still-unknown risks of such treatments in humans.

Comments

Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.

  • Everything has risks and benefits; nothing is safe. Should the FDA be the decisor? No, it is those who take the risks and hope for the benefits who should make intelligent decisions.

    • 20 May, 2008
    • Posted by: Herman Rubin